he contraction and relaxation of the beating heart are mediated by highly coordinated processes that allow rapid activation and deactivation of the myofilaments. The sarcomere is the fundamental contractile element, and its shortening is the result of the myosin-containing thick filament sliding past the actin-containing thin filament. Fueled by ATP hydrolysis, myosin is the molecular motor that drives sarcomere shortening through a cyclic, ratchet-like interaction with actin. A critical component of cardiac contraction is the regulation of myosin-actin interactions, which are governed predominantly by the thin-filament regulatory proteins troponin and tropomyosin.
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A change in myofilament isoform composition is one mechanism by which myocardial contractile performance may be affected in heart failure. The fast isoform of myosin heavy chain, ␣-MHC, normally accounts for approximately 10% of the fractional content in healthy human myocardium compared with 90% ␤-MHC, but it is reduced to nearly undetectable concentrations during heart failure. 1 In animal models, a change in myofilament performance can be detected with MHC isoform shifting, and the slight loss of ␣-MHC in human heart failure has been touted by some, 2 although not by all, 3 as an underlying factor in the reduced cardiac function. Enhanced incorporation of the atrial isoform of the myosin essential light chain in the failing human ventricle has been observed and correlates with an increase in myofilament calcium sensitivity. 4 Finally, a shift in troponin T isoform composition is reported in human heart failure, 5 with likely modest effects on contractility. 6 In this issue of Circulation, Rajan et al 7 identify a shift in tropomyosin isoform expression in human heart failure and investigate its possible functional consequences. As discussed, this study represents an important contribution to our understanding of how myofilament protein isoforms, through the cooperative activation of the thin filament, may influence cardiac performance in heart failure.
Tropomyosin is composed of 2 ␣-helical chains coiled around each other in a parallel fashion. It lies in the groove of actin helical filament spanning 40 nm (ie, 7 actin monomers), and in diastole, it blocks the myosin-binding sites on actin. For each tropomyosin molecule, there is a paired troponin molecule. Troponin contains 3 subunits: the calcium-binding troponin C, the inhibitory protein troponin I, and the tropomyosin-binding subunit troponin T. Troponin binds to tropomyosin and, in the absence of calcium, also binds to actin via troponin I. The myofilament is activated by calcium binding to troponin C, which induces a conformational change in troponin that results in decreased troponin I affinity to actin. 8 This effectuates an azimuthal shift of tropomyosin on the actin filament, which exposes myosinbinding sites on actin, and through the cyclic binding of myosin to actin, sarcomere shortening is initiated.
Continuous and coordinated contraction of the myocardium is the result of rapid contraction and relaxation of the myofilament. This process requires that the myofilament activation be highly cooperative. By definition, a cooperative biological process is one in which an action facilitates the same action in adjacent structures through an allosterically mediated change in protein conformation. 9 Perhaps one of the beststudied cooperative processes is the oxygen-hemoglobin association curve, in which at the level of the individual hemoglobin molecule the binding of 1 oxygen molecule greatly facilitates the occupancy of the remaining 3 oxygenbinding sites. Cardiac muscle activation is highly cooperative and occurs at several levels. The binding of calcium to troponin results in the exposure of myosin-binding sites along the 7 actin monomers blocked by the overlying tropomyosin molecule; however, activation of the thin filament likely extends beyond the confines of this 7-actin/tropomyosin/ troponin unit. Because the N and C termini of adjacent tropomyosins overlap by 9 amino acids, 10 the azimuthal shift of tropomyosin extends to neighboring tropomyosin molecules. Moreover, we now know from elegant kinetic 11 and structural 12 studies that calcium activation of the thin filament only partially exposes the myosin-binding site on the thin filament. The binding of 1 myosin molecule to the thin filament shifts tropomyosin further on actin, which fully exposes the adjacent actin-binding sites, which accelerates the rate of subsequent myosin binding to the thin filament. Finally, myosin binding to the thin filament increases the calcium affinity of unsaturated troponin C, which further accelerates the activation on the thin filament. 13 We are only beginning to understand the mechanisms underlying thin-filament regulation. Through myofilament cooperativity, even seemingly minor translational or posttranslational modifications to the regulatory proteins can have dramatic effects on thin-filament activation and contractility. Rajan et al 7 identify an increase in protein expression of a novel tropomyosin isoform (-tropomyosin) in human heart failure. In absolute terms, -tropomyosin expression is relatively small (3% to 5% of the total tropomyosin expressed), with ␣-tropomyosin being the predominantly expressed cardiac isoform (Ͼ90%). The authors, however, demonstrate a doubling of the expression of -tropomyosin in the failing human heart. To define the functional implication of an increase in -tropomyosin expression, an overexpression transgenic model was developed with the well-established ␣-MHC promoter. Human and mouse -tropomyosin are identical, which adds credibility to this approach. Three separate transgenic lines with differing levels of -tropomyosin expression were established. The transgenic mice developed a dilated cardiomyopathy highlighted by chamber dilation and decreased ejection fraction, which underscores the global functional significance of tropomyosin isoform shifting in myocardial function. Mechanical assessment of myofilament function in demembranated myocardial strips demonstrated decreases in both calcium-sensitive activation and myosin strong binding activation, with no effect on maximal force development.
To appreciate the potential underlying effects of -tropomyosin over ␣-tropomyosin, we need to better understand the possible structural differences. Although both tropomyosin isoforms are derived from the same gene (TMP1), the -isoform differs from the ␣-isoform by an exchange of exon 2 to the smooth muscle-specific exon (exon 2a). As originally defined by Crick et al, the protein ␣-helix is composed of 7 repeating amino acid motifs (termed positions  a, b, c, d , e, f, and g) for every 2 turns of the helix (Figure) . 14, 15 Positions a and d are generally apolar residues that permit stabilizing hydrophobic interactions between the 2 ␣-parallel helices of the coiled coil structure. Positions e and g are located on the outer surface of the tropomyosin molecule and stabilize the structure through salt bridges. Analysis of the primary sequence differences between exon 2b and 2a reveals substantial differences in these critical ␣-helical positions (see supplemental Table V in the article by Rajan et al). 7 On the basis of this analysis, it would be predicted that -tropomyosin would be substantially less stable (and thus more compliant) than ␣-tropomyosin. This was in fact demonstrated by the authors with thermal perturbation/circular dichroism experiments.
How can a change in tropomyosin stability lead to a decrease in thin-filament activation by calcium and myosin strong binding that ultimately affects myocardial mechanical performance at the whole-heart level? The answer likely lies in the critical contribution that tropomyosin plays in the cooperative activation of the myofilament. As indicated above, previous work indicates that through the overlapping of adjacent tropomyosin molecules, the regional activation of thin filament may be extended beyond the length of a single molecule. Although the degree to which cooperative activation extends down the thin filament generally has been thought to be less than 80 nm (ie, approximately 2 tropomyosin molecules), mechanical assays that detect a single myosin molecule interacting with a regulated thin filament have indicated that the cooperative activation of the thin filament with myosin strong binding may extend beyond 100 nm. 16 Recent data by Li et al 17 demonstrate through electron microscopy and molecular dynamic simulation that tropomyosin is a far more rigid molecule than previously appreciated, which raises the possibility that tropomyosin may be able to transmit cooperative activation as far as 1000 nm, or 25 lengths of tropomyosin. Thus, the relative compliance of the -tropomyosin isoform likely results in increased flexibility of tropomyosin, greatly shortening the cooperative distance that the thin filament is activated by either calcium or myosin binding. Although the amount of -tropomyosin expressed in the human heart is relatively small, the data presented by Li et al 17 would suggest that even a 1:25 protein stoichiometry could affect myofilament function.
More studies are needed to better define the functional consequences of increased -tropomyosin expression in human heart failure. It is generally accepted that there is increased thin-filament calcium sensitivity in failing human hearts. 18 Although marked overexpression of -tropomyosin in a mouse model leads to cardiomyopathic changes, the smaller increase in -tropomyosin expression in human heart failure may represent a partial compensatory mechanism aimed at reducing the calcium sensitivity of the thin filament toward the nonfailing state.
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Figure.
Helical relation of amino acid positions of the coiled coil of tropomyosin as viewed from an axial perspective. Hydrophobic residues at positions a and d stabilize interactions between ␣-helices, where positions g and e are typically charged amino acids that stabilize tropomyosin through ionic interactions.
